Skip to content
PeptideAI
Human trialsskin

Decapeptide-12

A non-cytotoxic tyrosinase inhibitor developed as a hydroquinone alternative, with real published melasma data behind it — unusual for this category.

Also known as Lumixyl, Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr, Lumixyl

Human trials — Studied in people, typically early phase or small — promising rather than proven.

One of the very few cosmetic peptides with a published, placebo-controlled human pigment trial, albeit a small pilot in recalcitrant melasma. The in-vitro tyrosinase inhibition data are solid; larger independent replication is still missing.

How it works

Decapeptide-12 was identified by screening peptide libraries against human tyrosinase and inhibits the enzyme roughly seventeen times more potently than kojic acid in vitro. The critical difference from hydroquinone is that it is not cytotoxic to melanocytes — hydroquinone works partly by damaging the pigment cell, which is why it carries ochronosis and permanent depigmentation risks with long use. Because decapeptide-12 only slows new melanin production, existing pigment must still turn over with the epidermis, which is why the published melasma work runs 12-16 weeks before the effect looks impressive. A split-face placebo-controlled pilot in recalcitrant melasma using 0.01% cream twice daily reported roughly 40% improvement at 12 weeks and 50% at 16 weeks.

Targets: Tyrosinase, Melanin biosynthesis

Dosing

ProtocolDoseFrequencyRoute
Melasma and hyperpigmentation protocolMorning and night, with mandatory broad-spectrum SPF 30+ over the morning application.—twice dailytopical
  • · The published pilot used 0.01% in an inert cream base — a very low concentration that still worked. Commercial products run 0.01-0.1%. Sunscreen is not an add-on here; without it the protocol fails.

Cycling

Run at least 16 weeks before judging it, then continue indefinitely for maintenance. Melasma recurs the moment suppression and photoprotection stop.

Work out your exact syringe units →

Pharmacology

Half-life
Not established.
Onset
Meaningful change takes 12-16 weeks. Anyone quoting four weeks is selling something.
Routes
topical
Molecule
Synthetic decapeptide
Sequence length
10 amino acids
Molecular weight
1395.5 Da

Handling

Diluent
Distilled or deionised water
Typical mix
20 or 50 mL
Vial sizes
50, 100, 200 mg
Lyophilised
Sealed, cool and dry; freezer for long-term.
Reconstituted
Refrigerated and preserved.
Light sensitive
Yes — keep it out of the light

Mixing

Water soluble. Skin penetration is the limiting factor for a 1395 Da peptide, which is why microneedling and dermal-infusion delivery have been studied alongside it.

Side effects

  • uncommonMild irritation— Markedly better tolerated than hydroquinone.

Combining it

  • synergymelanostatine-5 — Enzyme inhibition plus receptor blockade at different points in melanogenesis.
  • cautionhydroquinone — Often used sequentially rather than together — decapeptide-12 is typically the maintenance agent after a hydroquinone course.
  • conflictmelitane — Directly opposing effects on pigment.

What to monitor

  • · MASI or modified MASI scoring if you want a real number.
  • · Cross-polarised photographs at 0, 8 and 16 weeks.

Legal status

Cosmetic ingredient (INCI Decapeptide-12) approved worldwide; sold over the counter as Lumixyl.

References

  • Abu Ubeid et al. 2009, decapeptide-12 as a non-cytotoxic tyrosinase inhibitor (J Invest Dermatol) (preclinical)
  • Hantash & Jimenez 2009, split-face placebo-controlled pilot of an oligopeptide in recalcitrant melasma (J Drugs Dermatol) (trial)

Mechanism in depth

What makes decapeptide-12 worth taking seriously is not its potency but its safety mechanism, and the distinction from hydroquinone is the whole argument. Tyrosinase is a copper-containing enzyme that catalyses the two rate-limiting steps of melanogenesis: hydroxylation of tyrosine to DOPA, and oxidation of DOPA to dopaquinone. Almost every skin-lightening agent targets it. Hydroquinone does so partly by competitive inhibition and partly by being oxidised inside the melanocyte to reactive quinones that damage membrane lipids, mitochondria and DNA — it is cytotoxic to the pigment cell. That cytotoxicity is why it works well and also why prolonged use causes exogenous ochronosis and permanent confetti-like depigmentation, and why it is restricted or banned in many jurisdictions. Abu Ubeid and colleagues screened peptide libraries against mushroom and human tyrosinase and identified short sequences with inhibitory activity, reporting that treating melanocytes with 100 micromolar of their lead peptides for seven days reduced melanin content by 27% and 43% without the cytotoxicity that characterises hydroquinone. That is the selling point: enzyme inhibition without cell damage. The cost of that safety is exactly what you would expect — it only slows new melanin production, so existing pigment has to leave with epidermal turnover, which is why the published melasma work runs sixteen weeks rather than four. The frequently quoted claim of roughly seventeen-fold greater potency than kojic acid is an in-vitro enzyme comparison, not a clinical one.

What usually goes wrong

Quitting at week eight. The published pilot showed roughly 40% improvement at twelve weeks and 50% at sixteen, which means the curve is still climbing when most people give up. Sixteen weeks is the minimum honest assessment period. The second failure is skipping sunscreen, which is not a partial failure but a total one. The third is buying it at high concentrations: the published work used 0.01%, and products at 0.1% are not ten times better, they are ten times more expensive with a delivery ceiling that concentration does not raise — which is exactly why the developers went to microneedles and dermal infusion instead. Fourth, treating melasma as curable. It is a relapsing condition with hormonal, vascular and inflammatory drivers; suppression is the realistic goal and it needs to be permanent.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
Degraded by skin peptidases. No terminal protecting groups are described, which is unusual for a peptide of this size in a cosmetic.
Elimination
No meaningful systemic exposure.

Receptor targets

  • Human tyrosinase — Reported as substantially more potent than kojic acid in vitro; the seventeen-fold figure is an enzyme assay comparison

    Inhibits the rate-limiting steps of melanin biosynthesis without melanocyte cytotoxicity.

  • Melanin content in cultured melanocytes — Functional endpoint

    27-43% reduction after seven days at 100 micromolar in the original screening work.

Trials

  • Hantash & Jimenez split-face, double-blind, randomised, placebo-controlled pilot of a novel oligopeptide in recalcitrant melasma (J Drugs Dermatol) Randomised placebo-controlled pilot · n=5 · 16 weeks · 2009

    Statistically significant improvement in melasma appearance over 16 weeks with high patient satisfaction and no irritation or adverse reactions. Five participants — this is a pilot in the truest sense, but it is split-face, double-blind and placebo-controlled, which is more rigour than almost anything else in this class.

  • Kassim, Hussain & Goldberg open-label evaluation of a decapeptide-12 skin-brightening system (J Cosmet Laser Ther) Open-label · 2012

    Skin-brightening efficacy of the system. Open-label and uncontrolled, but independently authored rather than by the compound's developers.

  • Ramírez et al. open-label evaluation of 0.01% decapeptide-12 with 20% buffered glycolic acid in mild to moderate facial melasma (J Drugs Dermatol) Open-label · 2013

    Efficacy of the combined peptide plus glycolic acid system in facial melasma.

  • Bhatia, Hsu & Hantash combined topical delivery and dermal infusion of decapeptide-12 in post-inflammatory hyperpigmentation in skin of colour (J Drugs Dermatol) Clinical evaluation · 2014

    Accelerated resolution of post-inflammatory hyperpigmentation in skin of colour when topical application was combined with dermal infusion. Directly relevant because it shows the delivery route matters more than the concentration.

What to expect, and when

Week 0-8: little visible change. Week 12: roughly 40% improvement in the published pilot. Week 16: roughly 50%. Beyond 16 weeks: maintenance. Post-inflammatory hyperpigmentation responds faster than melasma because it is a self-limiting process you are accelerating rather than a chronic one you are suppressing.

Stacking and comparisons

Glycolic acid at 20% is the combination with published human data behind it, and the logic is good: the peptide suppresses new melanin while the acid accelerates turnover of the epidermis carrying existing melanin. That directly attacks the slow half of the timeline. Melanostatine-5 adds upstream receptor blockade for a genuinely non-overlapping combination. Tranexamic acid, oral or topical, adds the plasmin-inflammatory arm and is the best-evidenced melasma adjunct available. Hydroquinone is usually sequential rather than simultaneous — a hydroquinone course to clear, then decapeptide-12 for indefinite maintenance, which sidesteps the ochronosis risk of long hydroquinone use. Melitane is a direct conflict. And sunscreen is not an adjunct here, it is a component: without daily broad-spectrum SPF 30 or higher the protocol simply fails, because UV re-stimulates melanogenesis faster than tyrosinase inhibition suppresses it.

This is the second-best-evidenced compound in this entire class after botulinum toxin, and the best-evidenced of the genuine cosmetic peptides for pigment — it has a split-face, double-blind, placebo-controlled human trial, which nothing else in the pigment category has. It is also one of only two compounds here with independent replication from authors other than the developers. Against hydroquinone: safer, slower, smaller effect, no ochronosis risk, better as maintenance than as a clearing agent. Against tranexamic acid: oral tranexamic acid has larger randomised melasma trials and a bigger effect, at the cost of being a systemic antifibrinolytic with real contraindications. Against Melanostatine-5: downstream versus upstream, and this one has the trial.

Rough cost

$25–$120/month. Lumixyl-branded products are among the more expensive cosmetic peptide systems, typically $60-120 a month for the full regimen. Raw decapeptide-12 runs roughly $100-250 per gram, but at 0.01% a gram makes ten litres. Market observation, not a sourced pricing study.

Genuinely uncertain

  • The pivotal trial had five participants. It is well designed and it is still five people.
  • The seventeen-fold-more-potent-than-kojic-acid figure is an in-vitro enzyme comparison that does not translate to clinical potency.
  • No quantified skin permeation figure for decapeptide-12 exists, though the developers' own work implies it is poor enough to need enhancement.
  • The sequence Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr is widely reported for INCI Decapeptide-12 but I could not confirm it against a primary source.
  • The molecular weight of 1395.5 Da in the Core record is unconfirmed against a primary source.
  • Most of the human data come from Hantash and colleagues, who developed the compound. The Kassim study is the main independent replication and it is open-label.

Papers